Up 24% In A Month, Will CRISPR Stock Continue To See Higher Levels?

This article was originally published on Nasdaq

CRISPR Therapeutics stock (NASDAQ: CRSP), a biotechnology gene-editing company focused on developing gene-based medicines for human diseases, has risen a solid 24% in a month, outperforming the broader markets with the S&P500 down 8%. The recent rally in CRSP stock was led

Responses